Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy
The effect of thyroid suppression therapy (TST) on trabecular bone scores (TBS) and bone mineral density (BMD) in thyroidectomized women with differentiated thyroid carcinoma (DTC) on long-term follow-up is presently not conclusive. Patients and Methods. We carried out a study in 61 premenopausal and 84 postmenopausal Caucasian women with DTC. Serum biochemistry, bone markers, TBS, BMD, and bone fractures were evaluated 1–3 months post surgery and after a median follow-up of 10 years. Results. In the final study, patients belonged to Group I Premenopausal (n = 14) who remained in this status; Group II Premenopausal who became postmenopausal (n = 47); Group III patients who were and continued as postmenopausal (n = 84). Baseline premenopausal patients had a normal TBS mean value of 1.39 ± 0.14 significantly higher than that found in postmenopausal 1.31 ± 0.12 (p = 001). In the final study, premenopausal patients continued to have a normal TBS of 1.46 ± 0.08 compared to the significantly lower value of postmenopausal patients 1.25 ± 0.11 (p = 0.0009). Lumbar BMD (L-BMD) loss after the long-term study was significant in Group II (0.99 g/cm2 ± 0.13 vs. 0.91 ± 0.12 g/cm2, p < 0.0001) and there was a slight, but not significant, bone loss in Group I (1.00 ± 0.12 vs. 0.98 ± 0.11, p = 0.1936) and in Group III (0.86 ± 0.12 vs. 0.84 ± 0.15, p = 0.1924) compared with baseline values. Conclusion: Longer-term suppression therapy in female patients with DTC did not increase significantly the risk of bone loss, although we found in postmenopausal patients deterioration of bone microarchitecture. TBS study should be considered in the evaluation of postmenopausal DTC patients on long-term DTC for the evaluation of the risk of fractures.
KeywordsDifferentiated thyroid cancer Bone mineral density Trabecular bone score TSH suppression therapy
The authors thank Dr. Fernando Marin, M.D., Ph.D., for valuable help in the preparation of the manuscript.
This study was supported by a grant from the Foundation for the Investigation of Osteoporosis and Endocrine Diseases, Spain.
Study design: F.H. and S.G. Study conduct: M.M., B.L., E.F., J.I.M. Data adquisition: M.M. Data analysis: C.A. Data interpretation: F.H., S.G., M.M., G.M. Drafting manuscript: F.H., S.G., M.M., B.L. Revising manuscript content and approving final version of the manuscript: F.H., S.G.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 2.D.S. Cooper, B. Specker, M. Ho, M. Sperling, P.W. Ladenson, D.S. Ross, K.B. Ain, S.T. Bigos, J.D. Brierley, B.R. Haugen, I. Klein, J. Robbins, S.I. Sherman, T. Taylor, H.R. Maxon, Thyrotropin suppression and disease progression in patients with DTC. Results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 8, 737–744 (1998)CrossRefPubMedGoogle Scholar
- 9.B.R. Haugen, E.K. Alexander, K.C. Bible, G.M. Doherty, S.J. Mandel, Y.E. Nikiforov, F. Pacini, G.W. Randolph, A.M. Sawka, M. Schlumberger, K.G. Schuff, S.I. Sherman, J.A. Sosa, D.L. Steward, R.M. Tuttle, L. Wartofsky, 2015 American Thyroid Association Management guidelines for adult patients with thyroid nodules and differentiated thyroidcancer. Thyroid 26, 1–133 (2016)CrossRefPubMedPubMedCentralGoogle Scholar
- 13.L.Y. Wang, A.W. Smith, F. Palmer, R.M. Tuttle, A. Mahrous, I.J. Nixon, S.G. Patel, I. Ganly, J.A. Fagin, L. Boucai, Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma carcinoma. Thyroid 25, 300–307 (2015)CrossRefPubMedGoogle Scholar
- 18.E. Kamterewicz, E. Puigoriol, P. Peris, L. del Rio, P. Rosique, A. Yañez, y Grupo de Investigadores del estudio de fracturas Osteoporoticas de Osona. Relationship between C-telopeptides of type I collagen serum values with bone mineral density and antiosteoporotic drug intake in postmenopausal women. Preliminary data from the FRODOS study. Med. Clin. 16, 609–614 (2009)CrossRefGoogle Scholar
- 19.G. Mazziotti, A.M. Formenti, S. Frara, R. Olivetti, G. Banfi, M. Memo, R. Maroldi, R. Giubbini, A. Giustina, A high prevalence of radiological vertebral fractures inwomen on TSH suppressive therapy for thyroid carcinoma. J. Clin. Endocrinol. Metab. 103, 956–964 (2017). https://doi.org/10.1210/jc.2017-01986 CrossRefGoogle Scholar
- 22.S. Tournis, J.D. Antoniou, C.G. Liakou, J. Christodoulou, E. Papakitsou, A. Galanos, K. Makris, H. Marketos, S. Nikopoulou, I. Tzavaa, I.K. Triantafyllopoulos, I. Dontas, N. Papaioannou, G.P. Lyritis, M. Alevizaki, Volumetric bone mineral density and bone geometry assessed by peripheral quantative compute tomography in women with differentiated thyroid cancer under TSH suppression. Clin. Endocrinol. 82, 197–204 (2015)CrossRefGoogle Scholar